Parathyroid hormone update

被引：23

作者：

Hamann, Kendal L.

Lane, Nancy E.

机构：

[1] Univ Calif Davis, Med Ctr, Div Endocrinol, Sacramento, CA 95817 USA

[2] Sacramento Mather Vet Affairs Med Ctr, Mather, CA 95655 USA

[3] Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2006年 / 32卷 / 04期

关键词：

D O I：

10.1016/j.rdc.2006.07.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoporosis afflicts an estimated 10 million United States citizens, and approximately one in two women and one in four men who are older than the age of 50 will suffer from an osteoporosis-related fracture in their remaining lifetimes. US Food and Drug Administration (FDA)-approved therapies for the treatment and prevention of osteoporosis include calcium and vitamin D supplements and antiresorptive therapies. Recombinant human parathyroid hormone (rhPTH) and recombinant bioactive fragments of human parathyroid hormone (PTH) are emerging as a unique new class of treatment options for osteoporosis. This article briefly reviews the physiology and rationale for the use of PTH for the treatment of osteoporosis, and provides a more detailed update on the application of recent clinical trials of PTH to clinical practice.

引用

收藏

页码：703 / +

页数：19

相关论文

共 31 条

[1]

[Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General

[2] The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].

Black, DM ;

Greenspan, SL ;

Ensrud, KE ;

Palermo, L ;

McGowan, JA ;

Lang, TF ;

Garnero, P ;

Bouxsein, ML ;

Bilezikian, JP ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215

[3] One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[4] Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys [J].

Brommage, R ;

Hotchkiss, CE ;

Lees, CJ ;

Stancill, MW ;

Hock, JM ;

Jerome, CP .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3757-3763

[5] Daily and cyclic parathyroid hormone in women receiving alendronate [J].

Cosman, F ;

Nieves, J ;

Zion, M ;

Woelfert, L ;

Luckey, M ;

Lindsay, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :566-575

[6] Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal [J].

Cosman, F ;

Nieves, J ;

Woelfert, L ;

Formica, C ;

Gordon, S ;

Shen, V ;

Lindsay, R .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (05) :925-931

[7] Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial [J].

Deal, C ;

Omizo, M ;

Schwartz, EN ;

Eriksen, EF ;

Cantor, P ;

Wang, JY ;

Glass, EV ;

Myers, SL ;

Krege, JH .

JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (11) :1905-1911

[8] EVIDENCE THAT INTERMITTENT TREATMENT WITH PARATHYROID-HORMONE INCREASES BONE-FORMATION IN ADULT-RATS BY ACTIVATION OF BONE LINING CELLS [J].

DOBNIG, H ;

TURNER, RT .

ENDOCRINOLOGY, 1995, 136 (08) :3632-3638

[9] The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats [J].

Dobnig, H ;

Turner, RT .

ENDOCRINOLOGY, 1997, 138 (11) :4607-4612

[10]

*EL LILL CO, 2004, FORT PACK INS PA 924

← 1 2 3 4 →